Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8583-8601

  Chiu, Shih Hsin ^a,b   Wu, Chung Chun ^b   Fang, Chih Yeu ^b   Yu, Shu Ling ^b   Hsu, Hui Yu ^b   Chow, Yen Hung ^b   Chen, Jen Yang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

BALF3; Epstein Barr virus; Genomic instability; Nasopharyngeal carcinoma; Relapse

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALF3 GENE; CANCER RECURRENCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; EPSTEIN BARR VIRUS; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; TUMOR GROWTH; VIRUS GENE; VIRUS REACTIVATION; ANIMAL; CELL MOTION; CELL PROLIFERATION; COPY NUMBER VARIATION; DNA DAMAGE; DRUG SCREENING; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICRONUCLEUS; NASOPHARYNGEAL NEOPLASMS; NONOBESE DIABETIC MOUSE; PATHOGENICITY; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TIME; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANTINEOPLASTIC AGENT; BALF3 PROTEIN, HUMAN HERPESVIRUS 4; DEOXYRIBONUCLEASE; DNA BINDING PROTEIN; DOXYCYCLINE; VIRUS PROTEIN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; DNA COPY NUMBER VARIATIONS; DNA DAMAGE; DNA-BINDING PROTEINS; DOXYCYCLINE; ENDODEOXYRIBONUCLEASES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOMIC INSTABILITY; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE, INBRED NOD; MICE, SCID; MICRONUCLEI, CHROMOSOME-DEFECTIVE; NASOPHARYNGEAL NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907964892     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2323     Document Type: Article

References (113)

1. Yu MC and Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12(6):421-429.
2. Chang ET and Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765-1777.
3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS and Wang W Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21(4):631-637.
4. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX and Min HQ. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005; 23(6):1118-1124.
5. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL and Lau WH. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61(4):1107-1116.
6. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011; 117(9):1874-1883.
7. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS and Lee AW. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011; 79(2):420-428.
8. Wolf H, zur Hausen H and Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol. 1973; 244(138):245-247.
9. Luka J, Deeb ZE, Hartmann DP, Jenson B and Pearson GR. Detection of antigens associated with Epstein-Barr virus replication in extracts from biopsy specimens of nasopharyngeal carcinomas. J Natl Cancer Inst. 1988; 80(14):1164-1167.
10. Cochet C, Martel-Renoir D, Grunewald V, Bosq J, Cochet G, Schwaab G, Bernaudin JF and Joab I. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology. 1993; 197(1):358-365.
11. Martel-Renoir D, Grunewald V, Touitou R, Schwaab G and Joab I. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol. 1995; 76:1401-1408.
12. Sbih-Lammali F, Berger F, Busson P and Ooka T. Expres-sion of the DNase encoded by the BGLF5 gene of Epstein-Barr virus in nasopharyngeal carcinoma epithelial cells. Virology. 1996; 222(1):64-74.
13. Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, Middeldorp JM, Sham JS, Griffin BE and Ng MH. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol. 1998; 55(3):227-233.
14. Cabras G, Decaussin G, Zeng Y, Djennaoui D, Melouli H, Broully P, Bouguermouh AM and Ooka T. Epstein-Barr virus encoded BALF1 gene is transcribed in Burkitt's lymphoma cell lines and in nasopharyngeal carcinoma's biopsies. J Clin Virol. 2005; 34(1):26-34.
15. de-The G, Ho JH, Ablashi DV, Day NE, Macario AJ, Martin-Berthelon MC, Pearson G and Sohier R. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients. Int J Cancer. 1975; 16(5):713-721.
16. Henle G and Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976; 17(1):1-7.
17. Henle W, Ho JH, Henle G, Chau JC and Kwan HC. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer. 1977; 20(5):663-672.
18. Ho HC, Ng MH and Kwan HC. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br J Cancer. 1978; 37(3):356-362.
19. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z and Meng NN. Prospec-tive studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985; 36(5):545-547.
20. de-Vathaire F, Sancho-Garnier H, de-The H, Pieddeloup C, Schwaab G, Ho JH, Ellouz R, Micheau C, Cammoun M, Cachin Y and et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer. 1988; 42(2):176-181.
21. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ and Yang CS. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001; 345(26):1877-1882.
22. Cheng YC, Chen JY, Glaser R and Henle W. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 1980; 77(10):6162-6165.
23. Chen JY, Hwang LY, Beasley RP, Chien CS and Yang CS. Antibody response to Epstein-Barr-virus-specific DNase in 13 patients with nasopharyngeal carcinoma in Taiwan: a retrospective study. J Med Virol. 1985; 16(2):99-105.
24. Chen JY, Chen CJ, Liu MY, Cho SM, Hsu MM, Lynn TC, Shieh T, Tu SM, Lee HH, Kuo SL and et al. Antibo-dies to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma and control groups. J Med Virol. 1987; 23(1):11-21.
25. Chen JY, Chen CJ, Liu MY, Cho SM, Hsu MM, Lynn TC, Shieh T, Tu SM, Beasley RP, Hwang LY and et al. Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol. 1989; 27(4):269-273.
26. Liu MY, Chou WH, Nutter L, Hsu MM, Chen JY and YangCS. Antibody against Epstein-Barr virus DNA polymerase activity in sera of patients with nasopharyngeal carcinoma. J Med Virol. 1989; 28(2):101-105.
27. de Turenne-Tessier M, Ooka T, Calender A, de-The G and Daillie J. Relationship between nasopharyngeal carcinoma and high antibody titers to Epstein-Barr virus-specific thymidine kinase. Int J Cancer. 1989; 43(1):45-48.
28. Liu MY, Chang YL, Ma J, Yang HL, Hsu MM, Chen CJ, Chen JY and Yang CS. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma. J Med Virol. 1997; 52(3):262-269.
29. Lengauer C, Kinzler KW and Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396(6712):643-649.
30. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
31. Mitelman F, Mark-Vendel E, Mineur A, Giovanella B and Klein G. A 3q+ marker chromosome in EBV-carrying nasopharyngeal carcinomas. Int J Cancer. 1983; 32(6):651-655.
32. Kristensen M, Quek HH, Chew CT and Chan SH. A cytogenetic study of 74 nasopharyngeal carcinoma biopsies. Ann Acad Med Singapore. 1991; 20(5): 597-600.
33. Huang DP, Lo KW, Choi PH, Ng AY, Tsao SY, Yiu GK and Lee JC. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet. 1991; 54(1):91-99.
34. Huang DP, Lo KW, van Hasselt CA, Woo JK, Choi PH, Leung SF, Cheung ST, Cairns P, Sidransky D and Lee JC. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res. 1994; 54(15):4003-4006.
35. Hui AB, Lo KW, Leung SF, Choi PH, Fong Y, Lee JCand Huang DP. Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res. 1996; 56(14):3225-3229.
36. Mutirangura A, Tanunyutthawongese C, Pornthanakasem W, Kerekhanjanarong V, Sriuranpong V, Yenrudi S, Supiyaphun P and Voravud N. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer. 1997; 76(6):770-776.
37. Cheng R, Lo K, Huang D and Tsao S. Loss of heterozygosity on chromosome 14 in primary nasopharyngeal carcinoma. Int J Oncol. 1997; 10(5):1047-1050.
38. Tsang YS, Lo KW, Leung SF, Choi PH, Fong Y, Lee JCand Huang DP. Two distinct regions of deletion on chromosome 13q in primary nasopharyngeal carcinoma. Int J Cancer. 1999; 83(3):305-308.
39. Shao JY, Huang XM, Yu XJ, Huang LX, Wu QL, Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, Hu LF and Zeng YX. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res. 2001; 21(4B):3021-3029.
40. Chen YJ, Ko JY, Chen PJ, Shu CH, Hsu MT, Tsai SF and Lin CH. Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Gene, Chromosomes & Cancer. 1999; 25(2):169-175.
41. Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, Wong N, Choi PH, Lee JC and Huang DP. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer. 1999; 82(4):498-503.
42. Fan CS, Wong N, Leung SF, To KF, Lo KW, Lee SW, Mok TS, Johnson PJ and Huang DP. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol. 2000; 31(2):169-178.
43. Chien G, Yuen PW, Kwong D and Kwong YL. Comparative genomic hybridization analysis of nasopharygeal carcinoma: consistent patterns of genetic aberrations and clinicopathological correlations. Cancer Genet Cytogenet. 2001; 126(1):63-67.
44. Or YY, Hui AB, Tam KY, Huang DP and Lo KW. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol. 2005; 26(1):49-56.
45. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB and Chen JY. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene. 2004; 23(14):2531-2539.
46. Liu MT, Chang YT, Chen SC, Chuang YC, Chen YR, Lin CS and Chen JY. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Oncogene. 2005; 24(16):2635-2646.
47. Chen YR, Liu MT, Chang YT, Wu CC, Hu CY and Chen JY. Epstein-Barr virus latent membrane protein 1 represses DNA repair through the PI3K/Akt/FOXO3a pathway in human epithelial cells. J Virol. 2008; 82(16):8124-8137.
48. Pan SH, Tai CC, Lin CS, Hsu WB, Chou SF, Lai CC, Chen JY, Tien HF, Lee FY and Wang WB. Epstein-Barr virus nuclear antigen 2 disrupts mitotic checkpoint and causes chromosomal instability. Carcinogenesis. 2009; 30(2):366-375.
49. Deng YF, Zhou DN and Lu YD. Frequent allelic loss at the FRA3B site in endemic nasopharyngeal carcinoma: association with clinical features and Epstein-Barr virus infection. J Laryngol Otol. 2007; 121(11):1073-1078.
50. de-The G, Lavoue MF and Muenz L. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas. IARC Sci Publ. 1978; (20):471-481.
51. de-The G. (1982). Epidemiology of Epstein-Barr virus and associated diseases in man. In: Roizman B, ed. Herpesviruses. (New York, US: Plenum Press), pp. 25-103.
52. Okano M, Thiele GM, Davis JR, Grierson HL and Purtilo DT. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev. 1988; 1(3):300-312.
53. Crawford DH, (2004). Epstein-Barr virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, eds. Schoub BD, eds. Principles and Practice of Clinical Virology. (Chichester, UK: John Wiley & Sons, Ltd), pp. 123-146.
54. Lee CH, Fang CY, Sheu JJ, Chang Y, Takada K and Chen JY. Amplicons on chromosome 3 contain oncogenes induced by recurrent exposure to 12-O-tetradecanoylphorbol-13-acetate and sodium n-butyrate and Epstein-Barr virus reactivation in a nasopharyngeal carcinoma cell line. Cancer Genet Cytogenet. 2008; 185(1):1-10.
55. Fang CY, Lee CH, Wu CC, Chang YT, Yu SL, Chou SP, Huang PT, Chen CL, Hou JW, Chang Y, Tsai CH, Takada K and Chen JY. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer. 2009; 124(9):2016-2025.
56. Wu CC, Liu MT, Chang YT, Fang CY, Chou SP, Liao HW, Kuo KL, Hsu SL, Chen YR, Wang PW, Chen YL, Chuang HY, Lee CH, Chen M, Wayne Chang WS and Chen JY. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res. 2010; 38(6):1932-1949.
57. Chang YH, Lee CP, Su MT, Wang JT, Chen JY, Lin SF, Tsai CH, Hsieh MJ, Takada K and Chen MR. Epstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality. PloS one. 2012; 7(6):e39217.
58. Chiu SH, Wu MC, Wu CC, Chen YC, Lin SF, Hsu JT, Yang CS, Tsai CH, Takada K, Chen MR and Chen JY. Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle. J Virol. 2014; 88(9):4962-4975.
59. Fenech M. The in vitro micronucleus technique. Mutat Res. 2000; 455(1-2):81-95.
60. Fenech M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today. 2002; 7(22):1128-1137.
61. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273(10):5858-5868.
62. Lynn TC, Tu SM and Kawamura A Jr. Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol. 1985; 99(6):567-572.
63. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
64. Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering G, Williamson B and Clifford P. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci USA. 1966; 56(6):1699-1704.
65. Raab-Traub N, Hood R, Yang CS, Henry B and 2nd and Pagano JS. Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol. 1983; 48(3):580-590.
66. Raab-Traub N and Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell. 1986; 47(6):883-889.
67. Stolzenberg MC, Debouze S, Ng M, Sham J, Choy D, Bouguermouh A, Chan KH and Ooka T. Purified recombinant EBV desoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. Int J Cancer. 1996; 66(3): 337-341.
68. Ooka T, de Turenne-Tessier M and Stolzenberg MC. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol. 1991; 13(2):233-247.
69. Scheffczik H, Savva CG, Holzenburg A, Kolesnikova L and Bogner E. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 2002; 30(7):1695-1703.
70. Bhattacharyya SP and Rao VB. A novel terminase activity associated with the DNA packaging protein gp17 of bacteriophage T4. Virology. 1993; 196:34-44.
71. Oliveira-Costa JP, Oliveira LR, Zanetti JS, da Silveira GG, Buim MEC, Zucoloto S, Ribeiro-Silva A and Soares FA. BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma. Oncoscience. 2014; 1(5):383-391.
72. Xu E, Gong Y, Gu J, Jie L, Ajani JA and Wu X. Risk assessment of esophageal adenocarcinoma using γ-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1797-1804.
73. Bhatia A, Dey P, Goel S and Singh G. Expression of γH2AX may help in defining a genetically more stable subtype of infiltrating ductal carcinoma of breast. Indian J Med Res. 2013; 137(4):759-766.
74. Chatzimichail E, Matthaios D, Bouros D, Karakitsos P, Romanidis K, Kakolyris S, Papashinopoulos G and Rigas A. γ-H2AX: a novel prognostic marker in a prognosis prediction model of patients with early operable non-small cell lung cancer. Int J Genomics. 2014; 2014:160236.
75. Xie C, Xu LY, Yang Z, Cao XM, Li W and Lu NH. Expression of γH2AX in various gastric pathologies and its association with infection. Oncol Lett. 2014; 7(1):159-163.
76. Cheung WL, Albadine R, Chan T, Sharma R and Netto GJ. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J Urol. 2009; 181(3):1387-1392.
77. Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, Murakami T, Gondou T, Minami Y, Takemoto Y, Harada E, Tsushimi T, Li TS, Traganos F, Darzynkiewicz Z and Hamano K. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther. 2010; 9(3):246-252.
78. Su HF, Zhang XB, Fang M, He QC, Li WF and Wu SX. Protein microarray analysis on changes in protein phosphorylation in recurrent nasopharyngeal carcinoma. Zhonghua yi xue za zhi. 2011; 91(45):3219-3222.
79. Gou Y, Sun C, Hu L, He J, Zhang C, Feng Y, Zhang P, Kong X, Xiao L and Li Y. Correlation between DNA damage and EB virus infection in nasopharyngeal carcinoma. Xi bao yu fen zi mian yi xue za zhi. 2014; 30(2):184-187.
80. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging. 2011; 3(12):1130-1141.
81. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV and Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell cycle. 2009; 8(24):4112-4118.
82. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV and Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell cycle. 2009; 8(12):1888-1895.
83. Darzynkiewicz Z. When senescence masquerades as DNA damage: is DNA replication stress the culprit? Cell cycle. 2009; 8(23):3810-3811.
84. Morrison JA, Gulley ML, Pathmanathan R and Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 2004; 64(15):5251-5260.
85. Yip WK, Leong VC, Abdullah MA, Yusoff S and Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 2008; 19(2):319-328.
86. Chou CC, Chou MJ and Tzen CY. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol. 2009; 26(3):322-326.
87. Liu Y, Chen LH, Yuan YW, Li QS, Sun AM and Guan J. Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol. 2012; 33(1):241-245.
88. Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW and Chan AT. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Investigational New Drugs. 2010; 28(4):413-420.
89. Li YL, Zhang X, Liu Y, Li SS, Xie L, Zhang N, Liu XB and Tian YQ. Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma. Zhonghua er bi yan hou tou jing wai ke za zhi. 2010; 45(9):765-768.
90. Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK and Zhu XF. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PloS one. 2013; 8(3):e59879.
91. Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB and Chan AT. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Investigational New Drugs. 2013; 31(6):1399-1408.
92. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT, Sham JS and Ng MH. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer. 2007; 96(4):623-630.
93. Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, Huang TB, Ye W and Hong MH. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PloS one. 2011; 6(4):e19100.
94. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG and Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988; 54(6):831-840.
95. Orlandini M, Marconcini L, Ferruzzi R and Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA. 1996; 93(21):11675-11680.
96. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998; 95(2):548-553.
97. Manser E, Leung T, Salihuddin H, Zhao ZS and Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994; 367(6458):40-46.
98. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Munsterberg A, Vivian N, Goodfellow P and Lovell-Badge R. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 1990; 346(6281):245-250.
99. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998; 2(3):305-316.
100. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J and Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010; 42(7):599-603.
101. Zhao GG, Xiang XJ and He YJ. Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma. Ai zheng. 2007; 26(1):90-95.
102. Zhang Y, Peng J, Zhang H, Zhu Y, Wan L, Chen J, Chen X, Lin R, Li H, Mao X and Jin K. Notch1 signaling is activated in cells expressing embryonic stem cell proteins in human primary nasopharyngeal carcinoma. J Otolaryngol Head Neck Surg. 2010; 39(2):157-166.
103. Crook T, Nicholls JM, Brooks L, O'Nions J and Allday MJ. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene. 2000; 19(30):3439-3444.
104. Young LS and Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004; 4(10):757-768.
105. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS and Su GR. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer. 1982; 29(2):139-141.
106. Zeng Y. Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res. 1985; 44:121-138.
107. Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, Tse GM, Ding M, Li X, Lee JC and Huang DP. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000; 60(19):5365-5370.
108. Chan AS, To KF, Lo KW, Ding M, Li X, Johnson P and Huang DP. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer. 2002; 102(3):300-303.
109. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS and Qiu H. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer. 1992; 69(1):3-7.
110. Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM and Chuang SM. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest. 1990; 62(6):713-724.
111. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS and Li YP. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA. 1989; 86(23):9524-9528.
112. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57.
113. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1-13.